On November 20, ImmunityBio, Inc. fell 4.26% in Regular Trading, trading at $6.29 per share, with turnover of $13.1524 million.
The move aligned with continued market digestion of the company’s recent third-quarter results, which missed expectations on both revenue and adjusted earnings while net loss widened, continuing to pressure sentiment.
Third-quarter revenue was $48.841 million, below the $59.250 million consensus estimate. Adjusted EPS was a loss of $0.09 versus an expected loss of $0.08, while net loss widened to $0.18 per diluted share from $0.07 a year earlier. Although recent updates on Anktiva included Israeli regulatory approval, first patient treatment in Europe, and a bladder cancer registrational trial meeting its primary endpoint, those developments have not fully offset investor concern over financial performance and commercialization execution.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)